HMS Capital Management LLC Purchases 702 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

HMS Capital Management LLC increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,549 shares of the medical equipment provider’s stock after purchasing an additional 702 shares during the quarter. HMS Capital Management LLC’s holdings in Zimmer Biomet were worth $707,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Crewe Advisors LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter valued at $31,000. J.Safra Asset Management Corp boosted its stake in Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares in the last quarter. Bangor Savings Bank purchased a new stake in Zimmer Biomet in the third quarter worth about $31,000. Family Firm Inc. bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Zimmer Biomet during the second quarter valued at approximately $43,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $108.92 on Wednesday. The stock has a 50-day moving average price of $106.72 and a 200 day moving average price of $110.58. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The stock has a market capitalization of $21.68 billion, a P/E ratio of 20.71, a P/E/G ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.65 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date was Monday, September 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ZBH shares. Robert W. Baird reduced their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Truist Financial raised their price target on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a report on Friday, November 1st. Canaccord Genuity Group dropped their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Morgan Stanley reduced their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Royal Bank of Canada upped their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.